XL-413 explained

XL-413 is a drug which acts as a selective inhibitor of the enzyme cell division cycle 7-related protein kinase (CDC7). It is being researched for the treatment of some forms of cancer, and also has applications in genetic engineering.^{[1] [2] [3] [4]}

Notes and References

1. Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC . 6 . Discovery of XL413, a potent and selective CDC7 inhibitor . Bioorganic & Medicinal Chemistry Letters . 22 . 11 . 3727–31 . June 2012 . 22560567 . 10.1016/j.bmcl.2012.04.024 .
2. Sasi NK, Tiwari K, Soon FF, Bonte D, Wang T, Melcher K, Xu HE, Weinreich M . 6 . The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds . PLOS ONE . 2014 . 9 . 11 . e113300 . 25412417 . 10.1371/journal.pone.0113300 . 4239038 . 2014PLoSO...9k3300S . free .
3. Jin S, Ma H, Yang W, Ju H, Wang L, Zhang Z . Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1 . Journal of Molecular Medicine . 96 . 6 . 513–525 . June 2018 . 29713760 . 10.1007/s00109-018-1636-7 . 14036264 .
4. Wienert B, Nguyen DN, Guenther A, Feng SJ, Locke MN, Wyman SK, Shin J, Kazane KR, Gregory GL, Carter MA, Wright F, Conklin BR, Marson A, Richardson CD, Corn JE . 6 . Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair . Nature Communications . 11 . 1 . 2109 . April 2020 . 32355159 . 10.1038/s41467-020-15845-1 . 7193628 . 2020NatCo..11.2109W .